The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 5, 2010, Pages 301-307

  Okamoto, Isamu ^a   Mitsudomi, Tetsuya ^b   Nakagawa, Kazuhiko ^a   Fukuoka, Masahiro ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

epidermal growth factor receptor mutation; first line treatment; non small cell lung cancer; tyrosine kinase inhibitor

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PACLITAXEL; PLATINUM;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; FUNCTIONAL ASSESSMENT; GENE MUTATION; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; POINT MUTATION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 78649280568     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010370698     Document Type: Review

References (28)

1. Ando, M., Okamoto, I., Yamamoto, N., Takeda, K., Tamura, K., Seto, T. et al. (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24: 2549-2556.
2. Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H. et al. (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95: 998-1004.
3. Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I. et al. (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394-1400.
4. Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N. et al. (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340-3346.
5. Jackman, D.M., Miller, V.A., Cioffredi, L.A., Yeap, B.Y., Janne, P.A., Riely, G.J. et al. (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 15: 5267-5273.
6. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. ( 2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
7. Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Oizumi, S., Saijo, Y. et al. (2009) First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 27(suppl): abstr 8016.
8. Lee, J.S., Park, K., Kim, S.-W. et al. (2009) A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 4(Suppl): abstract PRS.4.
9. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
10. Mendelsohn, J. and Baselga, J. ( 2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799.
11. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J. et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
12. Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
13. Morita, S., Okamoto, I., Kobayashi, K., Yamazaki, K., Asahina, H., Inoue, A. et al. (2009) Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15: 4493-4498.
14. Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Takeda, K. et al. (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14: 922-930.
15. Okabe, T., Okamoto, I., Tamura, K., Terashima, M., Yoshida, T., Satoh, T. et al. (2007) Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67: 2046-2053.
16. Okamoto, I. ( 2010) Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 277: 309-315.
17. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
18. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I. et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
19. Politi, K., Zakowski, M.F., Fan, P.D., Schonfeld, E.A., Pao, W. and Varmus, H.E. ( 2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20: 1496-1510.
20. Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C. et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967.
21. Sequist, L.V., Martins, R.G., Spigel, D., Grunberg, S.M., Spira, A., Janne, P.A. et al. (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-2449.
22. Sordella, R., Bell, D.W., Haber, D.A. and Settleman, J. ( 2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
23. Sugio, K., Uramoto, H., Onitsuka, T., Mizukami, M., Ichiki, Y., Sugaya, M. et al. (2009) Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 64: 314-318.
24. Sunaga, N., Tomizawa, Y., Yanagitani, N., Iijima, H., Kaira, K., Shimizu, K. et al. (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III / IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 56: 383-389.
25. Sutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y. et al. (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95: 1483-1489.
26. Tamura, K., Okamoto, I., Kashii, T., Negoro, S., Hirashima, T., Kudoh, S. et al. (2008) Multicentre prospective phase II trial of gefitinib for advanced nonsmall cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98: 907-914.
27. Yang, C.H., Shih, J.Y., Chen, K.C., Yu, C.J., Yang, T.Y., Lin, C.P. et al. (2006) Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 107: 1873-1882.
28. Yoshida, K., Yatabe, Y., Park, J.Y., Shimizu, J., Horio, Y., Matsuo, K. et al. (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2: 22-28.